CD19 and neoplasm: Additionally, the whole-genome sequencing analysis of CD19 CAR-T-treated large B cell lymphoma patients indicated some tumor intrinsic aberrations, such as RHOA or RB1 deletions, APOBEC mutational activity, and chromothripsis events as characteristics for relapsed patients [118,119].